Journal article icon

Journal article

Evaluation of the clinical benefit of permixon® and tamsulosin in severe BPH patients - PERMAL study subset analysis

Abstract:

Objective: To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the α-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). Methods: In a 12-month, double-blind, randomized study that showed equivalent efficacy of Permixon 320 mg/day and tamsulosin 0.4 mg/day ("PERMAL study"), 685 BPH patients with IPSS ≥ 10 had been analyzed for efficacy. Of these, the 124 patients with severe LUTS (I...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Sub department:
Institute of Biomedical Engineering
Role:
Author
Expand authors...
Journal:
Progres en Urologie
Volume:
14
Issue:
3
Pages:
326-331
Publication date:
2004-06-01
ISSN:
1166-7087
Source identifiers:
121012
Language:
French
Keywords:
Pubs id:
pubs:121012
UUID:
uuid:bc56106d-7738-4495-9d0f-ef055bfdb4fc
Local pid:
pubs:121012
Deposit date:
2013-02-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP